Skip to content

A randomized controlled trial assessing the effects of the new erythritol air-polishing powder on microbiological and clinical outcomes during supportive periodontal therapy

A randomized controlled trial assessing the effects of the new erythritol air-polishing powder on microbiological and clinical outcomes during supportive periodontal therapy

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
DRKS
Registry ID
DRKS00005152
Enrollment
40
Registered
2013-07-18
Start date
2010-09-22
Completion date
Unknown
Last updated
2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

K05.3

Interventions

Group 1: Treatment of bleeding on probing positive (BoP+) sites with probing pocket depth (PPD) of =4mm but no detectable calculus through erythritol air-polishing in patients in periodontal maintenan

Sponsors

Elektro Medical Systems
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: Completion of active treatment for moderate to advanced chronic periodontitis, 2) absence of active periodontal therapy 3 months prior to enrollment, 3) presence of =2 teeth with a minimum of one BoP-positive site with a PPD of =4mm.

Exclusion criteria

Exclusion criteria: 1) any antibiotic therapy within 6 month prior to the study, 2) any indication for an endocarditis prophylaxis, 3) any diagnosis such as chronic bronchitis, asthma or a compromised immune system, and 4) any known hypersensitivity to sugar alcohol (polyol).

Design outcomes

Primary

MeasureTime frame
Number of test sites which do bleed after probing with a periodontal probe at baseline and six month after treatment with test or control treatment.

Secondary

MeasureTime frame
Reduction of probing pocket depth and of the clinical attachment level measured six month after initial treatment with test or control treatment. Microbiological differences measured at baseline and six month after treatment by analysis of a microbiological sample taken from study sites. Time to treat at baseline to treat study sites by test or control therapy.

Countries

Switzerland

Contacts

Public ContactAnton Sculean

Klinik für Parodontologie, Zahnmedizinische Kliniken der Universität Bern

anton.sculean@zmk.unibe.ch+41 31 632 25 89

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026